Seattle-based AltPep Corporation raised $23.15 million in a Series A financing round to take the company’s breakthrough amyloid targeting platform to development.

Part of the blame for limited testing availability for the coronavirus pandemic could fall squarely on the Centers for Disease Control (CDC), which used highly restrictive language in the health protection agency’s emergency use authorization for COVID-19 testing.